Ignite Creation Date:
2024-05-05 @ 11:45 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00121615
Status:
COMPLETED
Last Update Posted:
2009-03-06
First Post:
2005-06-30
Brief Title:
Study of Etanercept in the Treatment of Psoriasis in Adult Subjects
Sponsor:
Amgen
Organization:
Amgen
Study Overview
Official Title:
An Open-Label Long-Term Extension Study to Assess the Safety and Efficacy of Etanercept in the Treatment of Psoriasis in Adult Subjects
Status:
COMPLETED
Status Verified Date:
2009-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objective of the study is to describe the safety tolerability and efficacy of the long-term administration of etanercept in adults with psoriasis who have completed etanercept psoriasis study 20030115 or 20030117 in Canada and are continuing in a long-term extension Subjects from the 20030115 study will be followed for 24 months which began in Oct 2004 Subjects in the 20030117 study will be followed for 12 months which began in mid 2005
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None